Premium
N‐(3′,4′‐dimethoxycinnamonyl) anthranilic acid alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF‐ κ B activation
Author(s) -
Zhao Zhicheng,
Lu Li,
Li Weidong
Publication year - 2021
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21769
Subject(s) - lipopolysaccharide , western blot , myeloperoxidase , acute pancreatitis , chemistry , pancreas , medicine , pharmacology , inflammation , biochemistry , gene
Severe acute pancreatitis (SAP) can affect intestinal barrier with a high mortality. To date, effective therapies for SAP are still in urgently need. The purpose of this study was to investigate the role of anthranilic acid active synthetic derivative, N‐(3′,4′‐dimethoxycinnamonyl) anthranilic acid (3,4‐DAA), in intestinal barrier dysfunction of SAP. In this study, SAP mice model was induced by caerulein combined with lipopolysaccharide (LPS). SAP mice were pretreated with 3,4‐DAA orally. Histological structures of pancreatic and intestinal tissues were observed via hematoxylin–eosin (H&E) staining. Pancreas myeloperoxidase (MPO), serum lipase, and amylase were detected using corresponding kits. Western blot analysis and reverse transcription and quantitative PCR (RT‐qPCR) were employed to determine the levels of inflammatory factors in both pancreatic and intestinal tissues. Moreover, the levels of intestinal barrier‐related proteins, NLRP3 inflammasome and NF‐κB pathway were examined by western blot analysis. Result revealed that 3,4‐DAA significantly attenuated pancreas and intestine damage, inhibited the release of inflammatory factors and intestinal barrier dysfunction. Moreover, the expression of NLRP3 and phospho‐NF‐κB p65 in pancreatic and intestinal tissues was notably suppressed by 3,4‐DAA. To sum up, these results demonstrated that 3,4‐DAA could ameliorate SAP, partly attributing to the inhibition of intestinal barrier dysfunction and the release of inflammatory factors. These findings may provide a new mechanism support for 3,4‐DAA application in the clinical treatment of SAP.